

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5004217

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JIJUN YUAN	06/11/2018
XIANGDONG QU	06/11/2018
JUFANG LIN	06/11/2018
XIN YE	06/06/2018
GUOQING CAO	06/12/2018
WEIKANG TAO	06/07/2018
LIANSHAN ZHANG	06/07/2018
LEI ZHANG	06/07/2018
LI YANG	06/07/2018

RECEIVING PARTY DATA

Name:	SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
Street Address:	NO. 279 WENJING ROAD, MINHANG DISTRICT,
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	200245
Name:	JIANGSU HENGRUI MEDICINE CO., LTD.
Street Address:	NO. 7 KUNLUNSHAN ROAD
Internal Address:	ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE
City:	LIANYUNGANG, JIANGSU
State/Country:	CHINA
Postal Code:	222047

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15103758

CORRESPONDENCE DATA

Fax Number: (215)965-1331

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (215) 965-1330

Email:	adrake@panitchlaw.com
Correspondent Name:	PANITCH SCHWARZE BELISARIO & NADEL LLP
Address Line 1:	TWO COMMERCE SQUARE
Address Line 2:	2001 MARKET STREET, SUITE 2800
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103

ATTORNEY DOCKET NUMBER:	688452-69US
--------------------------------	-------------

NAME OF SUBMITTER:	WEIHONG HSING, PH.D.
---------------------------	----------------------

SIGNATURE:	/Weihong Hsing, Ph.D./
-------------------	------------------------

DATE SIGNED:	06/13/2018
---------------------	------------

	This document serves as an Oath/Declaration (37 CFR 1.63).
--	--

Total Attachments: 4

source=Combined Declaration and Assignment#page1.tif

source=Combined Declaration and Assignment#page2.tif

source=Combined Declaration and Assignment#page3.tif

source=Combined Declaration and Assignment#page4.tif

**INVENTOR'S COMBINED
DECLARATION (37 CFR 1.63) AND ASSIGNMENT
(Utility Patent Application)**

As a below-named inventor/assignor of a certain new and useful invention entitled:

**PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL
APPLICATION THEREOF**

DECLARATION

I hereby declare that:

This Declaration is directed to the patent application attached hereto or United States application or PCT Application number 15/103,758 filed on June 10, 2016.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this Declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Note to Inventor: 37 C.F.R. § 1.63(c) states: "A person may not execute an oath or declaration for an application unless that person has reviewed and understands the contents of the application, including the claims, and is aware of the duty to disclose to the Office all information known to the person to be material to patentability as defined in § 1.56."

ASSIGNMENT

WHEREAS, I ("ASSIGNOR") desire/am obligated to assign to the below-named ASSIGNEE the invention identified above;

WHEREAS, ("ASSIGNEE"):

Shanghai Hengrui Pharmaceutical Co., Ltd.
(a Chinese Corporation)
No. 279 Wenjing Road
Minhang District, Shanghai, 200245
People's Republic of China

AND

Jiangsu Hengrui Medicine Co., Ltd.
(a Chinese Corporation)
No.7 Kunlunshan Road
Economic and Technological Development Zone
Lianyungang, Jiangsu 222047
People's Republic of China

is desirous of acquiring the entire right, title and interest in and to the invention throughout the United States, and all right, title and interest in, to and under any and all Letters Patent of the United States resulting from the invention;

FOR GOOD and VALUABLE CONSIDERATION, the full receipt and sufficiency of which are hereby acknowledged, ASSIGNOR(S), intending to be legally bound, do hereby:

AUTHORIZE said ASSIGNEE, or its representatives to insert above the filing date and application number of the application when these are known;

SELL, ASSIGN, TRANSFER and CONVEY to ASSIGNEE the whole and entire right, title and interest for the United States and its possessions and territories in and to the invention which is disclosed in the above-identified patent application, and, in and to any and all patent applications related thereto including, but not limited to, all provisionals, non-provisionals, divisionals, continuations, continuations-in-part, substitutes, reexaminations, reissues and all other applications for patent which have been or shall be filed in the United States on the invention; all original, reissued and reexamined patents and extensions thereof which have been or shall be issued in the United States on the invention to the full end of the term or terms for which the patent(s) may be granted, as fully and entirely as the same would have been held by the undersigned ASSIGNOR(S) had this Assignment not been made; and specifically including all rights of priority created by the above patent application under any treaty, convention or law relating thereto;

AUTHORIZE and REQUEST the issuing authority to issue any and all United States patents granted on the invention to ASSIGNEE;

WARRANT and REPRESENT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by ASSIGNOR(S), and that the full right to convey the same as herein expressed is possessed by ASSIGNOR(S);

AGREE and UNDERTAKE, when requested and at the expense of ASSIGNEE, to carry out in good faith the intent and purpose of this Assignment, ASSIGNOR(S) will execute all non-


provisionals, divisionals, continuations, continuations-in-part, substitutes, reexaminations, reissues, and all other patent applications on the invention; execute all lawful oaths, declarations, assignments, powers of attorney and other papers; communicate to ASSIGNEE all facts known to ASSIGNOR(S) relating to the invention and the history thereof; and generally do everything possible which ASSIGNEE shall consider desirable for vesting title to the invention in ASSIGNEE, and for securing, maintaining and enforcing proper patent protection for the invention; all without further compensation to ASSIGNOR(S);

TO BE BINDING on the heirs, assigns, representatives and successors of ASSIGNOR(S) and extending to the successors, assigns, and nominees of ASSIGNEE.

First joint inventor/Assignor:

Date: 06/11/2018

Signature: _____




Typed Legal Name: Jijun Yuan

Second joint inventor/Assignor:

Date: 06/11/2018

Signature: _____




Typed Legal Name: Xiangdong Qu

Third joint inventor/Assignor:

Date: 06/11/2018

Signature: _____




Typed Legal Name: Jufang Lin

Fourth joint inventor/Assignor:

Date: 2018/06/06

Signature: _____



Typed Legal Name: Xin Ye

Fifth joint inventor/Assignor:


Date: 06/12/2018

Signature: _____




Typed Legal Name: Guojing Cao

Sixth joint inventor/Assignor:

Date: 7-June-2018 Signature: 

Typed Legal Name: Weikang Tao

Seventh joint inventor/Assignor:

Date: 7-June-2018 Signature: 


Typed Legal Name: Lianshan Zhang

Eighth joint inventor/Assignor:

Date: 7-June-2018 Signature: 

Typed Legal Name: Lei Zhang

Ninth joint inventor/Assignor:

Date: 7-June-2018 Signature: 

Typed Legal Name: Li Yang